Anti-histone and anti-nucleosome rather than anti-dsDNA antibodies associate with IFN-induced biomarkers in Sudanese and Swedish SLE patientsShow others and affiliations
2025 (English)In: Rheumatology, ISSN 1462-0324, E-ISSN 1462-0332, Vol. 64, no 3, p. 1170-1178Article in journal (Refereed) Published
Abstract [en]
Objectives In SLE, anti-dsDNA can co-occur with autoantibodies against other chromatin components, like histones and nucleosomes. These antibodies induce type-1 interferon production, a hallmark of SLE. We measured ANA sub-specificities and investigated their associations to inflammatory biomarkers including interferon-regulated chemokines.Methods We included 93 Sudanese and 480 Swedish SLE patients and matched controls (N = 104 + 192). Autoantibodies targeting ANA sub-specificities: dsDNA, Sm, Sm/U1RNPcomplex, U1RNP, SSA/Ro52, SSA/Ro60, SSB/La, ribosomal P, PCNA and histones were quantified in all subjects, anti-nucleosome only in the Swedish patients, with a bead-based multiplex immunoassay. Levels of 72 plasma biomarkers were determined with the Proximity Extension Assay technique or ELISA.Results Among Sudanese patients, the investigated antibodies were significantly associated with 9/72 biomarkers. Anti-histone antibodies showed the strongest positive correlations with MCP-3 and S100A12 as well as with interferon I-inducible factors MCP-1 and CXCL10. Anti-dsDNA antibodies were associated with CXCL10 and S100A12, but in multivariate analyses, unlike anti-histone, associations lost significance. Among Swedish patients, MCP-1, CXCL10, and SA100A12 also demonstrated stronger associations to anti-histone and anti-nucleosome antibodies, compared with anti-dsDNA and other ANA sub-specificities. In multiple regression models, anti-histone/nucleosome retained the strongest associations. When excluding anti-histone or anti-nucleosome positive patients, the associations between MCP-1/CXCL10 and anti-dsDNA were lost. In contrast, when excluding anti-dsDNA positive patients, associations with anti-histone and anti-nucleosome remained significant.Results Among Sudanese patients, the investigated antibodies were significantly associated with 9/72 biomarkers. Anti-histone antibodies showed the strongest positive correlations with MCP-3 and S100A12 as well as with interferon I-inducible factors MCP-1 and CXCL10. Anti-dsDNA antibodies were associated with CXCL10 and S100A12, but in multivariate analyses, unlike anti-histone, associations lost significance. Among Swedish patients, MCP-1, CXCL10, and SA100A12 also demonstrated stronger associations to anti-histone and anti-nucleosome antibodies, compared with anti-dsDNA and other ANA sub-specificities. In multiple regression models, anti-histone/nucleosome retained the strongest associations. When excluding anti-histone or anti-nucleosome positive patients, the associations between MCP-1/CXCL10 and anti-dsDNA were lost. In contrast, when excluding anti-dsDNA positive patients, associations with anti-histone and anti-nucleosome remained significant.Conclusion In two cohorts of different ethnical origins, autoantibodies targeting chromatin correlate stronger with IFN-induced inflammatory biomarkers than anti-dsDNA or other ANA sub-specificities. Our results suggest that anti-histone/nucleosome autoantibodies may be the main drivers of type-1 interferon activity in SLE.
Place, publisher, year, edition, pages
OXFORD UNIV PRESS , 2025. Vol. 64, no 3, p. 1170-1178
Keywords [en]
anti-chromatin antibodies; anti-dsDNA; SLE; interferon; proteome analysis; Africa
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:liu:diva-202279DOI: 10.1093/rheumatology/keae134ISI: 001193261800001PubMedID: 38460182Scopus ID: 2-s2.0-86000185548OAI: oai:DiVA.org:liu-202279DiVA, id: diva2:1850112
Note
Funding Agencies|Swedish Rheumatism Association [R-932093, R-840401]; King Gustav Vth 80-year foundation [FAI-2019-0577, FAI-2019- 0628]; Agnes and Mac Rudberg Foundation; Signe and Reinhold Sund's Foundation for Rheumatological Research; Swedish Society of Medicine; Ingegerd Johansson Donation [SLS-713911]; Swedish Research Council [2019-01632, 2018-02535]; Uppsala County Council; Stockholm County Council; Swedish Heart-Lung Foundation [20170257, 20190510]
2024-04-092024-04-092025-06-27